^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Excerpt:
...Participants were classified into 4 potential resistant mechanism groups (4 genetic/ 1 histologic) based on evaluation of rebiopsy tissue: EGFR mutations (T790M mutation, exon 20 insertion), KRAS mutations, MET amplification or small-cell lung cancer (SCLC) transform using established methods.`...
Trial ID:
Source:
Title:
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.
Published date:
12/10/2021
Excerpt:
CONTRADICTING EVIDENCE:...complex mutations in 24% of the patients with NSCLC who were evaluated for the study...18 patients with exon 20 insertion, 10 patients were male, and 50% were non-smokers. In this group, 7 patients (38.3%) received erlotinib, 6 patients (33.3%) afatinib, and 5 patients (27.7%) gefitinib. Median PFS of the whole group was 8.7 months (95% CI 3.1-14.3). In those who received erlotinib PFS was 7.0 months (95% CI 1.0-14.2), in afatinib treated patients PFS was 8.7 months (95% CI 1.0-20.5), and in gefitinib 15.0 months (95% CI 1.0-24.1) (p=0.479). Median OS was 26.4 months (95% CI 20.0-32.8) for the entire group. It was 24.0 months (95% CI 20.7-27.3) with erlotinib, 31.4 months (95% CI 22.7-40.1) with afatinib, and 28.5 months (95% CI 11.1-46.0) with gefitinib.
DOI:
10.21203/rs.3.rs-1125056/v1
Source:
Title:
145P-UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
Published date:
03/17/2021
Excerpt:
Uncommon mutation categories were: major uncommon (G719X, L861Q, S768I; 73%); compound (35%); ex20ins (12%); T790M (7%); other (9%). Most pts (n = 226; 92%) were treated in 1st-line with an EGFR TKI; 132 (54%), 70 (28%), 35 (14%) and 7 (3%) received afatinib, gefitinib, erlotinib and osimertinib....Overall median OS was 24.4 mos....ORR was 42% overall (major: 50%; compound: 49%; other: 44%; T790M: 20%; ex20ins: 17%); afatinib: 44% (DoR: 12.0 mos); 1st-gen TKIs: 44% (DoR: 11.0 mos)....Response was highest in pts with major uncommon, and/or compound mutations.
Trial ID:
Source:
Title:
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Excerpt:
Some of these include mutations known to be associated with sensitivity (L861Q) or resistance (exon 20 insertions) to EGFR-TKI. Other mutations or combinations of mutations...
DOI:
10.1158/1078-0432.CCR-09-0888
